Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02775383 · ClinicalTrials.gov registry record
The National Myelodysplastic Syndromes (MDS) Study
A clinical trial, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 2,115
- Enrollment target
NCT02775383: Completed study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT02775383 is a clinical trial that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 2,115 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02775383 has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 2,115 participants
- Enrollment target
Study Summary
Multi-center study enrolling patients suspected or newly diagnosed with myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlap disorder, or idiopathic cytopenia of undetermined significance (ICUS). Participants will be followed long term. Clinical data, blood, and tissue samples will be collected to establish a biorepository to facilitate the study of the natural history of MDS.
Primary Outcome
Deaths will be reported on study case report forms
Interventions
- OTHER Therapeutic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,115 participants |
| Start Date | 2016-06-13 |
| Est. Completion | 2025-12-31 |
What the finished NCT02775383 record still lists
NCT02775383 is an observational study that tracks outcomes without assigning an intervention. Its 2,115 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Therapeutic is the first listed.
NCT02775383 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02775383 about?
NCT02775383 is a clinical study titled "The National Myelodysplastic Syndromes (MDS) Study". Multi-center study enrolling patients suspected or newly diagnosed with myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlap disorder, or idiopathic cytopenia of undetermined significance (ICUS). Participants will be followed long term. Clinical d...
What is the current status of trial NCT02775383?
This trial is currently completed. The enrollment target is 2,115 participants. The study started on 2016-06-13. Estimated completion is 2025-12-31.
What interventions are being tested in trial NCT02775383?
The interventions under investigation include: Therapeutic (OTHER).
Who is sponsoring clinical trial NCT02775383?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05916430 · 2,120 participants
Screening for Autism in 9-Month-Olds by Measuring Social Visual Engagement
- NCT05681624 · 2,124 participants · NA
Maternal Oxygen Supplementation for Intrauterine Resuscitation
- NCT05967273 · 2,106 participants · NA
CirrhosisRx CDS System
- NCT07431281 · 2,130 participants · Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI